Core Insights - The beauty and personal care industry is transitioning from rapid growth to a focus on meticulous development, emphasizing research and innovation over marketing and distribution [1][3] Company Strategy - Betaini Group has formed a strategic partnership with Lumenis Group to enhance the home beauty device brand Tripollar in the Chinese market, focusing on deep operation and product innovation [1][3] - The collaboration is a significant step in extending the "medical-research co-creation" concept into the home beauty sector, leveraging over 20 years of skin science research and product development experience [3][4] Product Development - The core value of beauty devices lies in their safety and effectiveness, necessitating a deep integration of medical-grade technology and skin science [4] - Betaini is conducting clinical research to address the needs of Chinese consumers, particularly in sensitive skin anti-aging, optimizing energy parameters and waveform design to minimize potential irritation [4] - The Tripollar brand will evolve towards an integrated value proposition of "technology + scenario + service," transitioning from standalone devices to comprehensive solutions that include devices, specialized skincare essences, and online consultation services [4][6] Market Positioning - The home beauty device segment aligns with Betaini's mission to create a skin health ecosystem in China, focusing on high-tech and high-user engagement areas for sustainable development [6] - The company aims to redefine the home skin beauty industry through continuous investment and open collaboration, emphasizing the importance of creating trends rather than merely chasing them [6]

每经AI快讯，贝泰妮（SZ 300957，收盘价：45.97元）发布公告称，2025年9月，贝泰妮接受中金公司 等投资者调研，公司副总经理、财务总监、董事会秘书王龙等人回答了投资者提出的问题。 2025年1至6月份，贝泰妮的营业收入构成为：化妆品生产和销售占比99.42%，服务及其他占比0.58%。 每经头条（nbdtoutiao）——追忆管金生 | "拓荒者"的未竟事业 （记者 王晓波） ...

证券代码：300957 证券简称：贝泰妮 投资者关系活动记录表 编号：2025-007 | 投 资 者 | 关 | 系 活 | □特定对象调研 分析师会议 | | --- | --- | --- | --- | | 动类别 | | | □媒体采访 □业绩说明会 | | | | | □新闻发布会 路演活动 | | | | | 现场参观 | | | | □其他 | | | 参与单位名称 | | | 中金公司、东方财富、申万宏源证券、国海证券、WFM Asia、 | | | | | Aberdeen、工银瑞信、博时基金、富国基金、交银施罗德基 | | | | | 金、万家基金、华安基金、华宝基金、平安养老等 24 家机 | | | | 构 | | | 时间 | | 2025 | 年 9 月 | | 地点 | | | 线上、线下交流 | | 上 市 公 | 司 | 接 待 | 1、副总经理、财务总监、董事会秘书王龙 | | 人员姓名 | | | 2、投资者关系负责人张圣烨 | | | | 3、IR | 王丹琦 | | | | | Q：毛利率提升的主要原因，采取了哪些举措改善毛利？ A：公司聚焦推进战略换挡，收缩 ...

Core Viewpoint - The growing consumer demand for a better quality of life is driving the upgrade of the consumption industry, particularly in the beauty and personal care sector, where competition is shifting from marketing to research and innovation [1] Group 1: Strategic Collaboration - Betaini Group has formed a strategic partnership with Lumenis Group to advance the home beauty device brand Tripollar in the Chinese market, focusing on deep operation and product innovation [1][2] - The collaboration aims to extend the "medical-research co-creation" concept into home beauty, integrating home devices with Betaini's professional skincare products to provide consumers with advanced anti-aging solutions [2][3] Group 2: Technological Innovation - Betaini emphasizes technological innovation as a core driver for sustainable development, leveraging research platforms in various locations, including China and abroad, to create a global research ecosystem [2] - The partnership with Lumenis, which holds over 500 self-developed patents and extensive clinical literature, aims to transform professional medical technology into efficient and convenient home applications [3] Group 3: Product Development - Tripollar is shifting from a focus on hardware specifications to an integrated value proposition of technology, scenarios, and services, moving towards a system solution that combines devices, specialized skincare, and online consultation services [4] - The brand plans to address consumer pain points by introducing a "light care mode" suitable for fast-paced lifestyles, offering personalized usage suggestions and effect tracking [4] Group 4: Market Positioning - Betaini's operational strategy for Tripollar aligns with its overall direction, focusing on high-quality sustainable development by expanding into technology-driven and user-engaging sectors [5] - The home beauty device market is transitioning from marketing-driven growth to a phase where technological strength, clinical validation, and user experience are key drivers [5] Group 5: Future Outlook - Betaini intends to deepen its R&D collaboration with Lumenis, aiming to redefine the home skincare beauty industry and create trends rather than merely following them [6] - The company is exploring the integration of international leading technologies with Chinese skincare science, which not only opens new growth avenues for itself but also contributes to elevating the Chinese beauty industry on the global value chain [7]

Core Insights - The cosmetics sector experienced a rise of 1.51% on October 10, with Shuiyang Co. leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Company Performance - Shuiyang Co. (300740) closed at 23.93, up 8.72%, with a trading volume of 397,000 shares and a transaction value of 931 million yuan [1] - Jiahen Jiahua (300955) closed at 37.76, up 7.95%, with a trading volume of 119,800 shares and a transaction value of 438 million yuan [1] - Lafang Jiahua (603630) closed at 23.80, up 3.30%, with a trading volume of 73,600 shares and a transaction value of 17.5 million yuan [1] - Other notable performers include Bawi Co. (920123) up 2.45%, Shanghai Jahwa (600315) up 1.91%, and Jingsheng New Materials (300849) up 1.40% [1] Fund Flow Analysis - The cosmetics sector saw a net inflow of 96.14 million yuan from institutional investors, while retail investors experienced a net outflow of 98.20 million yuan [1] - Shuiyang Co. had a net inflow of 43.09 million yuan from institutional investors, but a net outflow of 33.48 million yuan from retail investors [2] - Jiahen Jiahua recorded a net inflow of 33.03 million yuan from institutional investors, with a significant net outflow of 67.04 million yuan from retail investors [2]

两年前花费巨资收购的子公司业绩承诺难以兑现，叠加近两年业绩大幅下滑，"药妆茅" 贝泰妮（300957）的转型正面临严峻考验。 对此，贝泰妮董秘回复称，公司始终致力于提升资产质量与运营效率，对所有投资项目均进行审慎管理。关于悦江投资的具体事项，公司将严格依据相关 协议与会计准则进行处理，切实维护上市公司及全体股东权益。投资悦江是公司从多品牌发展角度考虑的战略性布局。未来将通过集团赋能，逐步完善集 团的品牌矩阵，提升运营质量，充分发挥资产价值，为股东创造回报。 近日，贝泰妮在深交所互动易平台针对投资者关于"收购标的业绩承诺完成率不足三成"的追问，进行了回复。 有投资者提问："悦江投资承诺2023年~2025年净利润达到不低于2.35亿元，截至目前大概才完成7000万元，基本上完不成目标了，按照约定悦江投资无偿 转让19.6%的股权。对本公司来讲也是一个包袱，后期有计划转让持有的悦江投资股权吗？" 资料显示，云南贝泰妮生物科技集团股份有限公司成立于2010年，是一家集研发、生产和营销为一体，定位于皮肤健康互联网+的大健康产业集团。公司 于2021年3月25日登陆深交所创业板，为中国功效性护肤品第一股。目前，贝泰妮旗 ...

（编辑 王雪儿） 证券日报网讯 贝泰妮10月9日在互动平台回答投资者提问时表示，公司基于半年报披露时的市场环境作 出相关判断，并持续密切关注经营情况。目前公司各项业务正常开展，关于第三季度的具体财务与经营 数据，敬请关注公司后续披露的定期报告。 ...

Core Viewpoint - The company is experiencing short-term revenue pressure but demonstrates resilience in gross margin, with strategic adjustments in response to industry competition and consumer fatigue [1][2]. Financial Performance - Total revenue for H1 2025 is 2.372 billion (down 15.4% YoY), with net profit attributable to shareholders at 247 million (down 49.0% YoY) and net profit excluding non-recurring items at 183 million (down 56.5% YoY) [1]. - Gross margin and net profit margin stand at 76.0% and 10.5% respectively (up 3.4 percentage points and down 6.5 percentage points YoY) [1]. - Expense ratios for sales, management, and R&D are 54.2%, 8.1%, and 4.9% respectively (increased by 8.6, 1.9, and 0.8 percentage points YoY) [1]. Revenue Breakdown - Online channel revenue is 1.743 billion (down 6% YoY), with emerging content e-commerce platforms like Douyin showing growth; self-operated channels enhance repurchase rates through tiered membership operations, adding 430,000 new registered users [1]. - OMO channel revenue is 191 million (down 10% YoY) [1]. - Offline channel revenue is 424 million (down 42% YoY) [1]. Strategic Initiatives - The company is optimizing product structure and enhancing membership operations to improve gross margin, focusing on core products and reducing ineffective promotions [2]. - A multi-brand strategy is being deepened, with new growth avenues opened through the expansion of product lines and the acquisition of brands to cover various market segments [2]. - R&D efforts are concentrated on collaborative medical research and clinical efficacy validation, while channel strategies are shifting towards user operation and brand experience centers [2]. Investment Outlook - The company is positioned as a leader in effective skincare, with expected gradual recovery in performance driven by brand matrix, R&D barriers, and channel development [3]. - Projected net profits for 2025-2027 are 547 million, 642 million, and 777 million respectively, with a target valuation of 20.23 billion and a target price of 47.75 [3].

证 券 研 究 报 告 贝泰妮（300957）2025 年中报点评 中性（维持） 品牌矩阵与研发创新蓄力长期复苏 目标价：47.75 元 事项： 评论： 风险提示：市场竞争加剧、新品市场接受度不及预期等风险。 [主要财务指标 ReportFinancialIndex] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 5,736 | 5,406 | 5,952 | 6,655 | | 同比增速(%) | 3.9% | -5.8% | 10.1% | 11.8% | | 归母净利润(百万) | 503 | 547 | 642 | 777 | | 同比增速(%) | -33.5% | 8.7% | 17.4% | 21.1% | | 每股盈利(元) | 1.19 | 1.29 | 1.51 | 1.83 | | 市盈率(倍) | 38 | 35 | 30 | 25 | | 市净率(倍) | 3.2 | 3.0 | 2.8 | 2.7 | 资料来源：公司公告，华创证券预测 注：股价为 2025 年 9 ...

步入被称作"比难更难"的2025年，国货美妆行业的"退场名单"持续拉长，巧迪尚惠、境生之源、椿山、帷幕……这些曾在细分赛道有过声量的品牌都"倒 下"了。 行业寒冬下，新品牌的生存土壤也愈发贫瘠，从孵化到落地的每一步，都更具挑战性。但越是艰难的时候，越能见证国货美妆的破局魄力。庆幸的是，我 们看到2025年以来，行业不仅没有陷入新品牌停滞期，反而迎来一轮布局热潮。 如，上美股份一口气推出3个新品牌，贝泰妮酝酿三年的祛痘品牌进入待推倒计时，珀莱雅则意欲通过海外并购剑指婴童、香水、男士护肤等空白赛道， 就连半亩花田、方里、橘朵等中腰部品牌的母公司，也纷纷推出第二品牌…… 种种动作意味着，这些在处于领先地位的国货美妆企业们，正集体按下子品牌加速键，一场多品牌矩阵的攻坚战已全面打响。 头部企业扎堆"练小号" 今年布局子品牌的国货美妆中，既包含登陆资本市场的上市公司，也不乏处于行业中腰部的企业代表。 上市公司"多条腿并行" 于上市公司而言，当主品牌竞争到了一定阶段，往往会面临增长瓶颈，加之，企业为了触达更多细分人群，也需要拓宽市场覆盖维度。 这时候，"多条腿并行"就成为上市公司摆脱主品牌依赖、构建多元竞争力的重要战略选择 ...